Shots:
- The US FDA has granted approval to the company’s Leqselvi (8mg) tablets for treating severe alopecia areata adults
- Approval was supported by two P-III (THRIVE-AA1 & THRIVE-AA2) studies that assessed the scalp hair regrowth using the SALT score with Leqselvi (8mg or 12mg, BID) vs PBO in adults (n=1223; 18-65yrs.) with severe alopecia areata post 24wks. across the US, Canada & EU
- Avg. patients had 13% of scalp hair coverage at baseline. Study reached the 1EP, showing ≥80% scalp hair coverage (SALT ≤20) among 30% of patients with a consistent upward trend & no plateau after 24wks.; ~25% regained their scalp hair (≥90% coverage)
Ref: Sun Pharma | Image: Sun Pharma| Press Release
Related News:- Eli Lilly Reports the US FDA’s Approval of Kisunla (donanemab-azbt) to Treat Early Symptomatic Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
